AliquantumRx Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- (Upcoming)
- Latest Deal Amount
-
$750K
- Investors
-
3
AliquantumRx General Information
Description
Developer of a macrolide antibiotic platform designed to advance novel therapeutic applications across multiple high-impact disease areas. The company offers Cethromycin-HCl for use in treating dormant liver-stage malaria, tick-borne Babesiosis, drug-resistant bacterial infections, and biodefense threats such as inhalation anthrax and pneumonic plague, enabling healthcare providers to address unmet needs in infectious disease and biodefense with a single, promising therapeutic candidate.
Contact Information
Website
www.aliquantumrx.comCorporate Office
- 1812 Ashland Avenue
- Suite 100
- Baltimore, MD 21205
- United States
Corporate Office
- 1812 Ashland Avenue
- Suite 100
- Baltimore, MD 21205
- United States
AliquantumRx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | $750K | Upcoming | Clinical Trials - Phase 2 | |||
| 6. Grant | Completed | Pre-Clinical Trials | ||||
| 5. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 4. Grant | 02-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 25-Jan-2019 | Completed | Product Development | |||
| 2. Accelerator/Incubator | 14-Jan-2019 | $400K | Completed | Product Development | ||
| 1. Angel (individual) | 01-Jan-2019 | $400K | $400K | Completed | Product Development |
AliquantumRx Patents
AliquantumRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11697667-B2 | Salts and polymorphs of cethromycin for the treatment of disease | Active | 02-Dec-2019 | ||
| US-12391720-B2 | Salts and polymorphs of cethromycin for the treatment of disease | Active | 02-Dec-2019 | ||
| US-20210163522-A1 | Salts and polymorphs of cethromycin for the treatment of disease | Active | 02-Dec-2019 | ||
| US-20230312633-A1 | Salts and polymorphs of cethromycin for the treatment of disease | Active | 02-Dec-2019 | ||
| US-20250340583-A1 | Salts and polymorphs of cethromycin for the treatment of disease | Pending | 02-Dec-2019 | C07H17/08 |
AliquantumRx Signals
AliquantumRx Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| TEDCO | Venture Capital | Minority | ||
| Johns Hopkins Technology Ventures | Accelerator/Incubator | Minority | ||
| Triangle Angel Partners | Angel Group | Minority |
AliquantumRx FAQs
-
When was AliquantumRx founded?
AliquantumRx was founded in 2016.
-
Where is AliquantumRx headquartered?
AliquantumRx is headquartered in Baltimore, MD.
-
What is the size of AliquantumRx?
AliquantumRx has 6 total employees.
-
What industry is AliquantumRx in?
AliquantumRx’s primary industry is Drug Discovery.
-
Is AliquantumRx a private or public company?
AliquantumRx is a Private company.
-
What is AliquantumRx’s current revenue?
The current revenue for AliquantumRx is .
-
How much funding has AliquantumRx raised over time?
AliquantumRx has raised $900K.
-
Who are AliquantumRx’s investors?
TEDCO, Johns Hopkins Technology Ventures, and Triangle Angel Partners have invested in AliquantumRx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process